Clinical Research Directory
Browse clinical research sites, groups, and studies.
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Sponsor: Kyverna Therapeutics
Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis
Official title: KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3
Start Date
2024-08-06
Completion Date
2027-03
Last Updated
2025-10-08
Healthy Volunteers
No
Conditions
Interventions
KYV-101
Anti-CD19 CAR-T cell therapy
Standard lymphodepletion regimen
Standard lymphodepletion regimen
Locations (2)
Stanford University Medical Center
Palo Alto, California, United States
Northwell Health
Great Neck, New York, United States